FORA Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-16,752
| Closed | -$1.93M | – | 526 |
|
|
2024
Q3 | $1.93M | Buy |
+16,752
| New | +$1.93M | 0.23% | 133 |
|
|
2023
Q3 | – | Sell |
-2,298
| Closed | -$217K | – | 542 |
|
|
2023
Q2 | $217K | Sell |
2,298
-7,367
| -76% | -$695K | 0.03% | 316 |
|
|
2023
Q1 | $978K | Buy |
+9,665
| New | +$978K | 0.1% | 249 |
|
|
2022
Q4 | – | Sell |
-8,272
| Closed | -$879K | – | 601 |
|
|
2022
Q3 | $879K | Buy |
+8,272
| New | +$879K | 0.17% | 183 |
|
|
2021
Q3 | – | Sell |
-2,863
| Closed | -$279K | – | 684 |
|
|
2021
Q2 | $279K | Sell |
2,863
-258
| -8% | -$25.1K | 0.05% | 367 |
|
|
2021
Q1 | $304K | Buy |
+3,121
| New | +$304K | 0.1% | 227 |
|
|
2020
Q4 | – | Sell |
-2,204
| Closed | -$212K | – | 1060 |
|
|
2020
Q3 | $212K | Sell |
2,204
-3,341
| -60% | -$321K | 0.14% | 166 |
|
|
2020
Q2 | $676K | Buy |
+5,545
| New | +$676K | 0.23% | 118 |
|
|
2020
Q1 | – | Sell |
-8,281
| Closed | -$890K | – | 1226 |
|
|
2019
Q4 | $890K | Buy |
+8,281
| New | +$890K | 0.09% | 274 |
|